# Diabetes Research Hub — Monitor Report
**Run date:** 2026-10-06 (automated review; no existing files modified)

**Headline:** The data pipeline did NOT refresh since the 10-05 report. `clinical_trials_latest.json`, `pubmed_recent_latest.json`, and the gap files are all stamped 2026-10-05, and the newest snapshots are 10-05. Findings below are one day old. The tracker is 81 days stale. [Certain: file mtimes, snapshot diff 10-04 -> latest.]

## File System Status
| File | Last modified | Status |
|---|---|---|
| hub_monitor_report.md | 2026-10-05 | Fresh (1 day) |
| clinical_trials_latest.json (906 trials) | 2026-10-05 | Fresh |
| pubmed_recent_latest.json (162 papers) | 2026-10-05 | Fresh |
| literature_gap_data.json / literature_gap_report.md | 2026-10-05 | Fresh |
| Diabetes_Research_Tracker.xlsx | 2026-07-17 | **STALE: 81 days** |
| hub_monitor.py flag | | 882 live result files >14 days old (mostly audit/cache JSON) |

hub_monitor: 1545 files tracked, 3 new, 15 modified, 0 removed.
Open items: ACTION_REQUIRED_2026-09-21.md says `git push origin main` is blocked (no credentials in the sandbox). Latest ACTION_REQUIRED file is 15 days old; confirm whether the push happened.

## Clinical Trial Changes (10-04 -> 10-05)
- New 0, removed 0, status changes 0, new results 0. [Certain: monitor diff and my own key-level compare, both 906 trials.]
- Carry-over from the 10-05 report (weekly view): CagriSema NCT07817251 moved to RECRUITING; NCT06109311 (Lilly orforglipron, results posted 2026-10-01); NCT07112872 completion slipped 14 months.
- Counts: 906 trials; 282 recruiting; 143 Phase 3; Lilly 37 and Novo 30 trials. Sana: only NCT05791201 (Ph1/2).
- Registry results are unreviewed. Keep these BRONZE until tied to a verified paper.

## PubMed Highlights (162 papers, 17 domains, 30-day lookback)
- Sample, not census: 1,014 matched, 162 read (16%). Volume trends are not measurable at retmax=10.
- 10-04 -> 10-05: 6 new papers, 5 dropped. None are cross-domain. Newest: GLP-1 RA vs DPP-4i and dementia in COVID survivors (42831108), SGLT2i/GLP-1RA/DPP-4i and stroke (EClinicalMedicine, 42831062).
- 21 cross-domain papers in total. Highest value for Tier 1 Multi-Omics: 42824926 (renal tissue microbiota/metabolites in DKD; Biomarker x Microbiome x Multi-Omics).
- Key-therapy items (titles only, unreviewed): petrelintide ZUPREME 1 (Lancet D&E, 42810355); 3 teplizumab papers (42778314, 42767751, 42720752); several CagriSema/cagrilintide/amycretin reviews. Retatrutide/orforglipron Lancet/NEJM papers flagged on 10-05 remain in the data set.
- Note: survodutide obesity+T2D paper 42820639 dropped out of the 30-day window (window effect, not retraction).

## Gap Analysis Summary
Top 5 (all score 100.0, saturated): Beta Cell Regen x Health Equity (0 joint pubs); Insulin Resistance x Islet Transplant (1); Islet Transplant x GWAS/Polygenic (0); Islet Transplant x Personalized Nutr (0); Islet Transplant x Drug Repurposing (0).
- [Likely] Ranking is uninformative: 22 of the top 25 pairs sit at 100.0, and they are dominated by the smallest domains (Islet Transplant n=255, LADA 616, Drug Repurposing 626). Expected-count models inflate for small domains, and zero joint hits often reflect keyword-query mismatch. To reach [Certain], spot-check 3 pairs with MeSH-based queries.
- Tier 1 alignment: Drug Repurposing (Tier 1 #4) appears in 5 of the top 22 pairs; Health Equity and GWAS/omics pairs touch Tier 1 #1. Treat as hypotheses, not findings.

## Breaking News (web, standard search)
- Searches returned mostly aggregator and recap pages; I could not confirm any new Phase 3 readout or FDA action dated Sep 30 - Oct 6, 2026. Unverified leads: a PatientCare "5 FDA decisions from September 2026" roundup, and an Aug 30 "FDA approves new use of popular diabetes drug" local news item. Nothing flagged as significant. [Guessing: low yield from this query set.]

## Recommended Actions
1. Run `python baseline_clinical_trials.py` and `python baseline_pubmed_alerts.py` (data is 1 day old; the scheduled pipeline appears to have skipped 10-06 so far). Then `python hub_monitor.py`.
2. Update the tracker (81 days stale) with NCT06109311, NCT07817251 (now RECRUITING), and NCT06045221/NCT05872620.
3. Read abstracts for 42815506 (orforglipron CV safety), 42822480 (DIABIL-2 IL-2 T1D) and 42810355 (petrelintide) before assigning evidence levels.
4. Fix gap-score saturation (cap/normalise by domain size, or use MeSH-scoped queries) before using the top-25 list for contribution decisions.
5. Raise `domain_retmax` above 10 for the high-activity domains (AI/ML, GLP-1, Microbiome, Biomarker) to make volume trends meaningful.
6. Confirm `git push origin main` was done (see ACTION_REQUIRED_2026-09-21.md P0).
